Compare AJANTA PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PROCTER & GAMBLE HEALTH AJANTA PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 28.0 15.5 181.2% View Chart
P/BV x 7.8 6.2 125.0% View Chart
Dividend Yield % 0.5 7.6 5.9%  

Financials

 AJANTA PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
AJANTA PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,4223,549 40.1%   
Low Rs8981,301 69.0%   
Sales per share (Unadj.) Rs233.5511.4 45.7%  
Earnings per share (Unadj.) Rs44.061.3 71.7%  
Cash flow per share (Unadj.) Rs52.274.0 70.5%  
Dividends per share (Unadj.) Rs9.00440.00 2.0%  
Dividend yield (eoy) %0.818.1 4.3%  
Book value per share (Unadj.) Rs255.1927.8 27.5%  
Shares outstanding (eoy) m88.0216.60 530.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.7 104.7%   
Avg P/E ratio x26.439.6 66.7%  
P/CF ratio (eoy) x22.232.8 67.9%  
Price / Book Value ratio x4.52.6 173.9%  
Dividend payout %20.5717.9 2.9%   
Avg Mkt Cap Rs m102,08140,257 253.6%   
No. of employees `0006.81.1 599.6%   
Total wages/salary Rs m4,3071,313 328.1%   
Avg. sales/employee Rs Th3,022.67,486.7 40.4%   
Avg. wages/employee Rs Th633.41,157.6 54.7%   
Avg. net profit/employee Rs Th569.1897.2 63.4%   
INCOME DATA
Net Sales Rs m20,5548,490 242.1%  
Other income Rs m211244 86.4%   
Total revenues Rs m20,7658,734 237.7%   
Gross profit Rs m5,6641,482 382.3%  
Depreciation Rs m721211 341.3%   
Interest Rs m120-   
Profit before tax Rs m5,1431,514 339.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,273563 226.3%   
Profit after tax Rs m3,8701,017 380.4%  
Gross profit margin %27.617.5 157.9%  
Effective tax rate %24.837.1 66.6%   
Net profit margin %18.812.0 157.1%  
BALANCE SHEET DATA
Current assets Rs m11,81215,343 77.0%   
Current liabilities Rs m3,7761,960 192.7%   
Net working cap to sales %39.1157.6 24.8%  
Current ratio x3.17.8 40.0%  
Inventory Days Days7749 158.8%  
Debtors Days Days8228 286.8%  
Net fixed assets Rs m14,3981,209 1,190.6%   
Share capital Rs m175166 105.7%   
"Free" reserves Rs m22,27715,235 146.2%   
Net worth Rs m22,45215,401 145.8%   
Long term debt Rs m70-   
Total assets Rs m26,96217,595 153.2%  
Interest coverage x444.3NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 158.0%   
Return on assets %14.45.8 249.0%  
Return on equity %17.26.6 260.9%  
Return on capital %23.010.3 223.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,6821,636 652.8%   
Fx outflow Rs m2,1024,368 48.1%   
Net fx Rs m8,580-2,732 -314.1%   
CASH FLOW
From Operations Rs m3,748-1,304 -287.5%  
From Investments Rs m-2,22812,697 -17.5%  
From Financial Activity Rs m-1,475-301 490.7%  
Net Cashflow Rs m4511,093 0.4%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 1.6 18.2 8.5%  
FIIs % 7.6 1.0 760.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 29.1 58.4%  
Shareholders   20,968 28,591 73.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower, Dow Futures Down by 128 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 328 points, down 0.7% at 48,833 levels.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 12, 2021 01:09 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS